News Release

Why a liver disease target may need tuning, not switching off

A review links RNA acetylation to fatty liver disease, scarring and cancer, while highlighting the need to preserve antitumor immunity.

Peer-Reviewed Publication

Science China Press

How RNA acetylation links liver disease and antitumor immunity

image: 

The NAT10/ac4C system can support fat accumulation in hepatocytes, scar formation by hepatic stellate cells, and growth or treatment resistance in liver cancer cells. Its effects depend on the RNA target, cell type and disease stage. Reduced ac4C in certain myeloid immune cells may weaken antitumor immunity, highlighting the need to investigate treatments that target disease-promoting cells while preserving protective immune functions. The schematic summarizes the review's proposed framework rather than a clinically validated treatment.

view more 

Credit: ©Ying-li Zhu and Xiao-long Zhou / Medicine Plus. Reproduced from Figure 1 of the review

An enzyme implicated in liver fat buildup, scarring and cancer might seem an obvious target to switch off. But a review in Medicine Plus highlights a complication: suppressing the same system in certain immune cells could weaken the body's defenses against liver cancer. The authors argue that future treatments should focus not simply on blocking this pathway, but on controlling where, when and how strongly it is inhibited.

Written by Ying-li Zhu of the Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, and Xiao-long Zhou of the Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, the review brings together research on an enzyme called NAT10 and the RNA modification it installs, N4-acetylcytidine (ac4C). It proposes a framework for understanding their changing roles across liver disease.

An extra control on the cell's instructions

Cells use messenger RNA to carry instructions for making proteins. Chemical marks on these messages can influence how long the instructions remain available and how efficiently they are read. NAT10 can add ac4C to RNA, helping selected messages last longer or produce more protein. However, the effects vary with the message and the position of the mark.

The authors describe this system as an epitranscriptomic rheostat: a molecular dimmer switch rather than a simple on-off switch. Its output depends on which RNA is modified, which cell contains it and the stage of disease. This distinction helps explain why targeting the same enzyme could have different consequences across the liver.

From excess fat to scar tissue and cancer

In hepatocytes, the liver's main working cells, studies reviewed by the authors link NAT10 to RNA messages that support fat production. By stabilizing these messages, the system may amplify pathways involved in metabolic dysfunction-associated steatotic liver disease, or MASLD. Reducing NAT10 activity has lessened liver fat accumulation in preclinical models, although the precise modification sites and effects on normal metabolism need further investigation.

In hepatic stellate cells, which help produce scar tissue after injury, NAT10 has been linked to longer-lasting messages that promote fibrosis. This may reinforce a self-sustaining cycle of cell activation and scar formation. An important unanswered question is whether targeting the system can reverse established fibrosis, rather than merely slow its development.

In hepatocellular carcinoma, the review describes links between NAT10/ac4C and tumor growth, spread and treatment resistance. Studies discussed in the article implicate the system in cellular stress responses and resistance to lenvatinib, a targeted cancer drug. These findings support further investigation, but do not establish a treatment for patients.

Protecting the cells that fight cancer

The therapeutic challenge becomes clearer when immune cells enter the picture. The review highlights research in which reduced ac4C in myeloid immune cells weakened antitumor responses and reduced the effectiveness of immunotherapy. This raises the possibility that a drug acting throughout the body could inhibit cancer cells while also undermining immune functions needed to control the tumor.

For that reason, the authors favor investigating cell-selective approaches. Potential strategies would direct inhibition toward disease-promoting liver cells or tumor cells while preserving activity in protective immune compartments. Partial inhibition may also offer a safer balance than complete suppression, but the degree needed for benefit without harm remains unknown.

Turning a framework into a treatment

Before this approach can move toward clinical use, researchers need detailed maps of ac4C in different liver cells, evidence identifying which RNA changes actually drive disease, and more selective tools to test NAT10 inhibition. The review also flags unresolved questions about whether ac4C can be broadly removed by a dedicated enzyme and how it interacts with other RNA modifications.

Safety is central. NAT10 contributes to normal RNA modification and protein production, so reducing its activity could affect healthy tissue as well as diseased cells. The authors call for measurements that establish whether an intervention reaches its intended target and for studies that assess liver function, regeneration and immune competence alongside therapeutic effects.

The review's central message is that NAT10/ac4C is neither universally harmful nor universally protective. Understanding its context-dependent roles could guide future strategies for fatty liver disease, fibrosis and liver cancer, but clinical benefit and a safe treatment window still need to be established.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.